OTC:CC - Ocumetics Announces Successful Completion of Animal Studies
(TheNewswire)
Calgary, A B - TheNewswire - February 13, 2023 - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Company ”) ( TSXV:OTC) (OTC:OTCFF)(FRA:2QBO) is pleased to announce the successfulcompletion of its latest animal studies. “The purpose of thesestudies was to test our latest design,” said Dr. Garth Webb,Ocumetics’ Founder and Chief Scientific Officer. “The lensdesign met and exceeded our expectations. It is exciting to see thetechnology we have developed over the years coming tofruition.”
Ocumetics’ Chief Medical Officer, Dr. Doyle Stulting,said “The latest design addresses the needs of ophthalmologists,with the lens exiting the injector during surgery at a controlled paceand gently expanding to fill the capsular bag. In addition, the newlens addresses all of the feedback we had received from our MedicalAdvisory Board.”
Dr. Mark Lee, Ocumetics’ President & CEO,advises, “This is the first in a series of biocompatibility studies,the second of which is scheduled to commence in March 2023. Thebiocompatibility studies will take 3 months to complete, which meanswe should be able to begin our first-in-human proof of concept studiesin July or August of 2023. We are very pleased with these latestresults and look forward to beginning the first humanstudies.”
About Ocumetics
Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO)is a Canadian research and development company that specializes inadaptive intraocular lens designs. Ocumetics is in the preclinicalstudy stage of a game-changing technology for the ophthalmic industry. Ocumetics has developed an expandable intraocular lens that fitswithin the capsular bag following extracapsular cataract extraction. It is designed to allow the eye’s natural muscle activity to shiftfocus from distance to near, potentially to eliminate the need forcorrective lenses.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dr. Mark Lee
President and CEO
(604) 832-6052
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to,statements with respect to the commencement, timing and scope of theclinical trial program outlined above and that it will be conducted asexpected. Forward- looking statements arenecessarily based upon a number of estimates and assumptions that,while considered reasonable, are subject to known and unknown risks,uncertainties, and other factors which may cause the actual resultsand future events to differ materially from those expressed or impliedby such forward-looking statements. Such factors include but are notlimited to: operational matters, historical trends, current conditionsand expected future developments, access to financing as well as otherconsiderations that are believed to be appropriate in thecircumstances. There can be no assurance that such statements willprove to be accurate, as actual results and future events could differmaterially from those anticipated in such statements. Accordingly,readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update orrevise any forward-looking statements, whether as a result of newinformation, future events or otherwise, except as required bylaw.
Copyright (c) 2023 TheNewswire - All rights reserved.